array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2512) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(81) "France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal" ["snippet_en"]=> string(247) "The companies said the deal will give Sanofi access to Inhibrx's INBRX-101, currently in the second of three phases of clinical trials, while its other experimental drugs will be spun off into a separate company, with Sanofi retaining an 8% stake." ["url"]=> string(75) "https://ca.finance.yahoo.com/news/frances-sanofi-buy-u-drugs-063215685.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6e936cb5-7957-4f27-9507-368074f4ff67" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2024-01-23" ["categories"]=> array(4) { [0]=> string(11) "Acquisition" [1]=> string(15) "Deals & Tenders" [2]=> string(20) "Business Development" [3]=> string(25) "Business Model Resilience" } } [1]=> array(7) { ["title_en"]=> string(90) "Eckert & Ziegler: Important decision expected in Q1 – is the share now picking up speed?" ["snippet_en"]=> string(155) "Eckert & Ziegler is considering selling or listing its subsidiary Pentixapharm. This could secure financing for the expansion of the radioisotope business." ["url"]=> string(130) "https://www.deraktionaer.de/artikel/aktien/eckert-ziegler-wichtige-entscheidung-im-q1-erwartet-aktie-nimmt-fahrt-auf-20347025.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/36dda04d-1d07-45ea-bdf2-9b5610d92a39" ["source"]=> string(15) "deraktionaer.de" ["publication_date"]=> string(10) "2024-01-07" ["categories"]=> array(4) { [0]=> string(11) "Acquisition" [1]=> string(18) "Expansion & Growth" [2]=> string(25) "Business Model Resilience" [3]=> string(10) "Divestment" } } [2]=> array(7) { ["title_en"]=> string(57) "Europe remains the poor relation of major steel maneuvers" ["snippet_en"]=> string(160) "Faced with Japanese-American and Chinese initiatives, the asset sales announced by certain European groups do not meet the need for consolidation in the sector." ["url"]=> string(107) "https://www.agefi.fr/news/entreprises/leurope-reste-le-parent-pauvre-des-grandes-man%C5%93uvres-dans-lacier" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f8c5a454-c1da-4330-b5f9-c65fe81e07ea" ["source"]=> string(8) "agefi.fr" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(9) { [0]=> string(6) "Energy" [1]=> string(11) "Acquisition" [2]=> string(11) "Competition" [3]=> string(9) "Valuation" [4]=> string(21) "Competitive Behaviour" [5]=> string(25) "Business Model Resilience" [6]=> string(14) "Issuing Shares" [7]=> string(6) "Merger" [8]=> string(19) "Foreign Development" } } [3]=> array(7) { ["title_en"]=> string(42) "Bristol-Myers Jumps on Billion-Dollar Buzz" ["snippet_en"]=> string(107) "Bristol-Myers Squibb (BMY) is rising after news that the company is acquiring Karuna (KRTX) for $14 billion" ["url"]=> string(101) "https://www.schaeffersresearch.com/content/news/2023/12/22/bristol-myers-jumps-on-billion-dollar-buzz" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d20a8e15-3230-4678-9aa6-591b57fa63e0" ["source"]=> string(22) "schaeffersresearch.com" ["publication_date"]=> string(10) "2023-12-22" ["categories"]=> array(2) { [0]=> string(11) "Acquisition" [1]=> string(25) "Business Model Resilience" } } [4]=> array(7) { ["title_en"]=> string(74) "Bristol-Myers plans billion-dollar acquisition | Stock exchanges newspaper" ["snippet_en"]=> string(105) "The pharmaceutical company Bristol-Myers Squibb plans to take over Karuna. The deal is worth $14 billion." ["url"]=> string(88) "https://www.boersen-zeitung.de/unternehmen-branchen/bristol-myers-plant-milliardenzukauf" ["image_url"]=> string(78) "https://images.businessradar.com/articles/63bf47c9-fc1c-4117-ac8e-9e357e28b031" ["source"]=> string(18) "boersen-zeitung.de" ["publication_date"]=> string(10) "2023-12-22" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(21) "Competitive Behaviour" [2]=> string(25) "Business Model Resilience" [3]=> string(12) "Stock Market" [4]=> string(15) "Deals & Tenders" } } [5]=> array(7) { ["title_en"]=> string(65) "Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors" ["snippet_en"]=> string(65) "Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors" ["url"]=> string(108) "https://in.investing.com/news/aurinia-pharmaceuticals-shares-surge-on-gilead-acquisition-rumors-93CH-3908497" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-11-21" ["categories"]=> array(7) { [0]=> string(15) "Market Movement" [1]=> string(11) "Acquisition" [2]=> string(24) "Stock Research & Ratings" [3]=> string(25) "Business Model Resilience" [4]=> string(14) "Issuing Shares" [5]=> string(12) "Stock Market" [6]=> string(9) "Investors" } } [6]=> array(7) { ["title_en"]=> string(40) "Bartec intends to sell the food division" ["snippet_en"]=> string(167) "Bartec intends to sell the Food and BMS (Food) division of Bartec Benke in Gotteszell to Ultrakust, a company in the medium-sized segment of the Lübeck Possehl Group." ["url"]=> string(89) "https://www.verfahrenstechnik.de/bartec-beabsichtigt-verkauf-des-geschaeftsbereichs-food/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e585400b-7bf7-42df-be8c-8524a568c6f2" ["source"]=> string(20) "verfahrenstechnik.de" ["publication_date"]=> string(10) "2023-11-13" ["categories"]=> array(4) { [0]=> string(11) "Acquisition" [1]=> string(23) "Supply Chain Management" [2]=> string(25) "Business Model Resilience" [3]=> string(10) "Divestment" } } [7]=> array(7) { ["title_en"]=> string(59) "Century Supply Chain Solutions Leverages the Slync Platform" ["snippet_en"]=> string(88) "Slync, Inc. (“Slync.io”) today announced that its Logistics Orchestration technology" ["url"]=> string(159) "https://wheels.report/featured-news/century-supply-chain-solutions-leverages-the-slync-platform-to-streamline-origin-logistics-and-drive-operational-efficiency" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f55c91a9-d675-4609-8320-05b555d396b9" ["source"]=> string(13) "wheels.report" ["publication_date"]=> string(10) "2023-03-23" ["categories"]=> array(5) { [0]=> string(12) "Board Change" [1]=> string(11) "Acquisition" [2]=> string(25) "Business Model Resilience" [3]=> string(23) "Supply Chain Management" [4]=> string(23) "Supply Chain Disruption" } } [8]=> array(7) { ["title_en"]=> string(133) "Heart Failure Market Report (2022 to 2030) – Tenax Therapeutics, Novartis Ag, Bayer Ag, Bristol-Myers Squibb, Eli Lilly And Company" ["snippet_en"]=> string(296) "Pune, Jan. 09, 2023( GLOBE NEWSWIRE) -- According to a new market research report titled,“ Heart Failure Market by Type( Acute Heart Failure and Chronic Heart Failure) and by Therapeutic Drugs( Cardiac Glycosides, Sympathomimetic Agents, Phosphodiesterase III inhibitors, Diuretics, Aldosterone" ["url"]=> string(78) "https://finance.yahoo.com/news/heart-failure-market-report-2022-141900575.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/640e01de-30be-45af-8948-5545aad8baf3" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-01-09" ["categories"]=> array(4) { [0]=> string(11) "Competition" [1]=> string(25) "Business Model Resilience" [2]=> string(5) "R & D" [3]=> string(15) "Market Movement" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(252) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(165) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(153) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(87) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(78) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(75) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [8]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(57) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(55) } [13]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(46) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(46) } [16]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(41) } [19]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(36) } [20]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(34) } [22]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(6) "Energy" ["count"]=> int(22) } [29]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company